Bisphosphonate use and subsequent hip fracture in South Korea. - Wikidata - awgldk - TriplyDB

Bisphosphonate use and subsequent hip fracture in South Korea.

Bisphosphonate use and subsequent hip fracture in South Korea.

http://www.wikidata.org/entity/Q38107388

about

Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysis Physicians' attitudes to contemporary issues on osteoporosis management in Korea Undertreatment of osteoporosis following hip fractures in jeju cohort study.Risk of hip fractures in men with alpha-blockers: a nationwide study base on claim registry.Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study.Parameters Pointing at an Increased Risk for Contralateral Hip Fractures: Systematic Review.Incidence, Morbidity and Mortality in Patients Older than 50 Years with Second Hip Fracture in a Jeju Cohort Study.Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database National utilization of calcium supplements in patients with osteoporotic hip fracture in Korea.Characteristics of Patients Diagnosed with Osteoporosis in South Korea: Results from the National Claim Registry.Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial.Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.Subtrochanteric femoral stress fracture with features of atypical femoral fracture in patient with Paget's disease: a case report.Improvement of Osteoporosis Medication after Multimodal Intervention in Patients with Hip Fracture: Prospective Multicenter Study.

P2860

Q26749442-38935B70-2667-42EF-B1C4-622B1FBCD0AF Q33822047-3EDB717F-52E7-41AB-81CA-83095A56BA73 Q34627973-B87B8B94-8E28-4770-8878-F515132F6B0E Q35171406-CADB2048-BBC5-4B67-B5D9-4C4E1B3FA430 Q35739607-4A52AE6A-3BF9-4AC2-B88E-200DCC7368E3 Q36564818-80586E07-3B45-4FF6-ADEB-40EAAB1EFDE8 Q37147679-18156719-557B-437C-B28C-FB32D07545F9 Q37168515-00779169-C805-46A7-9817-76D434CE426E Q37542738-F321435D-1389-4F7C-AF55-55FE2359412E Q37710327-02F0FA3E-9627-4E27-B7F9-8CCF65829BFB Q39064322-833CD8FA-46D1-4F14-B41F-9E213C2EE898 Q40313121-63125212-0001-441F-8489-D3CF776B2EA1 Q49465302-F0101460-5F8C-4ABE-9B1E-C35931D798B8 Q55288624-A32F9D3C-0009-4767-A85E-6C16395F230F

P2860

Bisphosphonate use and subsequent hip fracture in South Korea.

http://www.wikidata.org/entity/Q38107388

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bisphosphonate use and subsequent hip fracture in South Korea.

@en

type

label

Bisphosphonate use and subsequent hip fracture in South Korea.

@en

prefLabel

Bisphosphonate use and subsequent hip fracture in South Korea.

@en

P1433

Q38107388-57B07704-A7FB-4E9A-83A4-93543862225E

P1476

Q38107388-26B3563E-4D4A-4A2C-903F-A534027FAE4E

P2093

Q38107388-0B83CA53-F221-44DD-9A63-766EB5177164

Q38107388-6BA09641-29D8-444C-BC42-CA2C751CFB2E

Q38107388-9F88A51F-F2AC-4331-9BCF-E7EA6BD62D71

Q38107388-A42ED4B1-6ABA-4B01-81A9-D63C5A4EAAB7

Q38107388-A89B0BBF-EA45-45ED-BE88-76433CA533B8

Q38107388-F353925D-9D6B-40EE-8493-543448BF5C9A

P2860

Q38107388-09298E82-3EBB-415E-AED5-2665629DBB91

Q38107388-0C557BBE-FD55-4580-9593-1DDD6120EDEE

Q38107388-1A2F73AB-F6FD-4427-AF09-73FDA7386F36

Q38107388-359EB7EA-C12E-4376-8A7B-982F49A26301

Q38107388-47D58ADA-65D2-4F22-8DBD-2FC10CFA9776

Q38107388-4C356C84-8718-482B-8445-71827BFD4F1E

Q38107388-51356CA4-4E96-4A35-989C-1A44503A00DB

Q38107388-52EF08EA-EDF3-46EC-8154-3AB9CC55E409

Q38107388-55CE1201-CFD9-45C7-BAAE-B6E7D4938DE2

Q38107388-571DBB49-B955-4B58-9110-4D538ADF1015

P2888

Q38107388-9532B1BC-046E-4AF7-851B-0172516AF81B

P304

Q38107388-9670CFBE-0F4D-491A-8A93-2420C5C006FD

P31

Q38107388-7248F58B-57D9-48DF-90DB-A9495135BFB8

P356

Q38107388-C7AA4CBC-7961-457D-86F0-77EBAC41282C

P407

Q38107388-F33E30DB-783B-4C6A-A086-B05142BA7B5E

P433

Q38107388-3A3E1683-89F8-48B6-82FE-ABC4E18F7E6D

P478

Q38107388-C8FE140C-CF1D-4257-A025-B347395E3717

P50

Q38107388-2A9659EE-9C08-4EDC-ABC4-9B037F95417A

P577

Q38107388-30D136CE-8726-4133-BB0A-5CE440228018

P6179

Q38107388-1DDB68EC-25B1-471B-BB2F-3558E3C4A666

P698

Q38107388-7CF3B31F-72D6-4BE3-B750-09B30B0D7D0F

P356

S00198-013-2395-5

P1433

Osteoporosis International

P1476

Bisphosphonate use and subsequent hip fracture in South Korea

@en

P2093

C Park

http://www.w3.org/2001/XMLSchema#string

C S Shin

http://www.w3.org/2001/XMLSchema#string

S Jang

http://www.w3.org/2001/XMLSchema#string

Y-C Ha

http://www.w3.org/2001/XMLSchema#string

Y-K Lee

http://www.w3.org/2001/XMLSchema#string

Y-T Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence and mortality of hip fracture among the elderly population in South Korea: a population-based study using the national health insurance claims data.

Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

Minimizing disparities in osteoporosis care of minorities with an electronic medical record care plan

Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture.

Incidence and mortality following hip fracture in Korea.

Orthopedic surgeon's awareness can improve osteoporosis treatment following hip fracture: a prospective cohort study.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Non-compliance: the Achilles' heel of anti-fracture efficacy.

P2888

s00198-013-2395-5

P304

2887-2892

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-013-2395-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1032394507

http://www.w3.org/2001/XMLSchema#string

P698

23681088

http://www.w3.org/2001/XMLSchema#string